BRVE · Insider Trading
Braveheart Bio, Inc. Common Stock
Every open-market purchase and sale reported by BRVE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Erez Chimovits | Director | MIXED | +11,072,420 | +$34.92M |
| 2026-08-11 | ORBIMED ADVISORS LLC | Director | MIXED | +11,072,420 | +$34.92M |
| 2026-08-11 | Marc L Andreessen | 10%+ Owner | MIXED | +10,232,420 | +$19.80M |
| 2026-08-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | C | +7,420,091 | — |
| 2026-08-07 | Forbion Ventures VII Management B.V. | 10%+ Owner | MIXED | +20,723,287 | +$64.80M |
| 2026-08-07 | David I Malek | Director | Buy | +4,166 | +$74.99K |
| 2026-08-07 | James Paul Rickey | Chief Financial Officer | Buy | +27,777 | +$499.99K |
| 2026-08-07 | Christopher Viehbacher | Director | Buy | +83,333 | +$1.50M |
| 2026-08-07 | Michele A. Anderson | Chief Development Officer | Buy | +1,111 | +$20.00K |
| 2026-08-07 | Travis Murdoch | CEO and President | Buy | +83,333 | +$1.50M |
| 2026-08-07 | Jasper Bos | Director | A | +30,000 deriv. | — |
| 2026-08-07 | Erez Chimovits | Director | A | +30,000 deriv. | — |
| 2026-08-07 | Tim Lohoff | Director | A | +30,000 deriv. | — |
| 2026-08-07 | David Charles Lubner | Director | Buy | +55,555 | +$999.99K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Forbion Ventures Fund VII Cooperatief U.A. | 10%+ Owner | 20,146,024 | $405.04M |
| Forbion Ventures VII Management B.V. | 10%+ Owner | 18,226,024 | $366.43M |
| Erez Chimovits | Director | 10,235,159 | $205.78M |
| Marc L Andreessen | 10%+ Owner | 9,132,420 | $183.61M |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | 7,420,091 | $149.18M |
| Travis Murdoch | CEO and President | 3,968,066 | $79.78M |
| David I Malek | Director | 773,571 | $15.55M |
| Christopher Viehbacher | Director | 759,857 | $15.28M |
| James Paul Rickey | Chief Financial Officer | 612,251 | $12.31M |
| Michele A. Anderson | Chief Development Officer | 332,161 | $6.68M |
| ORBIMED ADVISORS LLC | Director | 273,333 | $5.50M |
| David Charles Lubner | Director | 55,555 | $1.12M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BRVE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.